PTC Therapeutics up 5% on mid-stage Huntington's disease asset data

• PTC Therapeutics (NASDAQ:PTCT) is up ~5% in Wednesday morning trading after reporting promising phase 2 data on its Huntington's disease candidate PTC518.
• Results showed that the asset led to a dose-dependent lowering of Huntingtin (HTT) protein levels in peripheral blood cells, achieving a mean 30% reduction in mutant HTT levels at the 10mg dose level at 12 weeks.
• No treatment-related serious adverse events, reports of peripheral neuropathy or dose-limiting toxicities were reported.

More on PTC Therapeutics

• PTC Therapeutics: Rare Disease Specialist's Stock In Danger Of Slipping Further

• PTC Therapeutics: A Gem In The Rare Diseases Treatment Market